Amgen started off the fiscal year with an earnings beat, reporting $5.6 billion in revenues in the first quarter and net income of $1.99 billion, or $3.48 per share. Revenue for the Thousand Oaks-based biotech giant was flat to the previous first quarter and narrowly beat expectations of $5.54 billion among average analyst estimates. Net…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
